Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway

Journal of Dermatological Science

Volumn 85, Issue 1, 2017, Pages 20-26

  Bissonnette, Robert ^a   Fuentes Duculan, Judilyn ^b   Mashiko, Shunya ^c   Li, Xuan ^b   Bonifacio, Kathleen M ^b   Cueto, Inna ^b   Suárez Fariñas, Mayte ^d   Maari, Catherine ^a   Bolduc, Chantal ^a   Nigen, Simon ^a   Sarfati, Marika ^c   Krueger, James G ^b  

^a INNOVADERM RESEARCH   (Canada)

^b ROCKEFELLER UNIVERSITY   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

IL 17; IL 23; Palmoplantar psoriasis; Palmoplantar pustular psoriasis; Psoriasis; Skin biopsies

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; INTERLEUKIN 17; INTERLEUKIN 19; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; CYTOKINE; IL17A PROTEIN, HUMAN; IL23A PROTEIN, HUMAN; INTERLEUKIN 23P19; PEPTIDOGLYCAN; PNEUMOCOCCAL PURPURA-PRODUCING PRINCIPLE;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ETHNICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN MANIFESTATION; ADOLESCENT; AGED; BIOPSY; COMPARATIVE STUDY; CYTOLOGY; ELBOW; LEG; MAST CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; PSORIASIS; SCALP; SKIN; TRUNK; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOPSY; CYTOKINES; ELBOW; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; INTERLEUKIN-23 SUBUNIT P19; LEG; MALE; MAST CELLS; MIDDLE AGED; PEPTIDOGLYCAN; PSORIASIS; QUALITY OF LIFE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCALP; SIGNAL TRANSDUCTION; SKIN; TORSO; YOUNG ADULT;

EID: 85001889471     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2016.09.019     Document Type: Article

References (28)

1. [1] Baliwag, J., Barnes, D.H., Johnston, A., Cytokines in psoriasis. Cytokine 73:2 (2015), 342–350.
2. [2] Chiricozzi, A., Saraceno, R., Chimenti, M.S., Guttman-Yassky, E., Krueger, J.G., Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?. Expert Opin. Ther. Targets 18:5 (2014), 513–525.
3. [3] Girolomoni, G., Mrowietz, U., Paul, C., Psoriasis: rationale for targeting interleukin-17. Br. J. Dermatol. 167:4 (2012), 717–724.
4. [4] Tausend, W., Downing, C., Tyring, S., Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J. Cutan. Med. Surg. 18:3 (2014), 156–169.
5. [5] Rich, P., Sigurgeirsson, B., Thaci, D., Ortonne, J.P., Paul, C., Schopf, R.E., Morita, A., Roseau, K., Harfst, E., Guettner, A., Machacek, M., Papavassilis, C., Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br. J. Dermatol. 168:2 (2013), 402–411.
6. [6] Papp, K.A., Leonardi, C., Menter, A., Ortonne, J.P., Krueger, J.G., Kricorian, G., Aras, G., Li, J., Russell, C.B., Thompson, E.H., Baumgartner, S., Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366:13 (2012), 1181–1189.
7. [7] Volpe, E., Servant, N., Zollinger, R., Bogiatzi, S.I., Hupe, P., Barillot, E., Soumelis, V., A critical function for transforming growth factor-beta interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 9:6 (2008), 650–657.
8. [8] Gaffen, S.L., Jain, R., Garg, A.V., Cua, D.J., The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 14:9 (2014), 585–600.
9. [9] Mashiko, S., Bouguermouh, S., Rubio, M., Baba, N., Bissonnette, R., Sarfati, M., Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J. Allergy Clin. Immunol. 136:2 (2015), 351–359.
10. [10] Lin, A.M., Rubin, C.J., Khandpur, R., Wang, J.Y., Riblett, M., Yalavarthi, S., Villanueva, E.C., Shah, P., Kaplan, M.J., Bruce, A.T., Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol. 187:1 (2011), 490–500.
11. [11] Lynde, C.W., Poulin, Y., Vender, R., Bourcier, M., Khalil, S., Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J. Am. Acad. Dermatol. 71:1 (2014), 141–150.
12. [12] Frleta, M., Siebert, S., McInnes, I.B., The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr. Rheumatol. Rep., 16(4), 2014, 414.
13. [13] Chung, J., Callis Duffin, K., Takeshita, J., Shin, D.B., Krueger, G.G., Robertson, A.D., Troxel, A.B., Van Voorhees, A.S., Edson-Heredia, E., Gelfand, J.M., Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J. Am. Acad. Dermatol. 71:4 (2014), 623–632.
14. [14] Sevrain, M., Richard, M.A., Barnetche, T., Rouzaud, M., Villani, A.P., Paul, C., Beylot-Barry, M., Jullien, D., Aractingi, S., Aubin, F., Joly, P., Le Maitre, M., Cantagrel, A., Ortonne, J.P., Misery, L., Treatment for palmoplantar pustular psoriasis: systematic literature review evidence-based recommendations and expert opinion. J. Eu. Acad. Dermatol. Venereol.: JEADV 28:Suppl. 5 (2014), 13–16.
15. [15] Brunasso, A.M., Puntoni, M., Aberer, W., Delfino, C., Fancelli, L., Massone, C., Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br. J. Dermatol. 168:6 (2013), 1243–1251.
16. [16] Kubota, K., Kamijima, Y., Sato, T., Ooba, N., Koide, D., Iizuka, H., Nakagawa, H., Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open, 5(1), 2015, e006450.
17. [17] Murakami, M., Hagforsen, E., Morhenn, V., Ishida-Yamamoto, A., Iizuka, H., Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp. Dermatol. 20:10 (2011), 845–847.
18. [18] Hagforsen, E., Hedstrand, H., Nyberg, F., Michaelsson, G., Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br. J. Dermatol. 163:3 (2010), 572–579.
19. [19] Murakami, M., Kaneko, T., Nakatsuji, T., Kameda, K., Okazaki, H., Dai, X., Hanakawa, Y., Tohyama, M., Ishida-Yamamoto, A., Sayama, K., Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS One, 9(10), 2014, e110677.
20. [20] Bissonnette, R., Nigen, S., Langley, R.G., Lynde, C.W., Tan, J., Fuentes-Duculan, J., Krueger, J.G., Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J. Eur. Acad. Dermatol. Venereol.: JEADV 28:10 (2014), 1298–1305.
21. [21] Lee, E., Trepicchio, W.L., Oestreicher, J.L., Pittman, D., Wang, F., Chamian, F., Dhodapkar, M., Krueger, J.G., Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199:1 (2004), 125–130.
22. [22] Fuentes-Duculan, J., Suarez-Farinas, M., Zaba, L.C., Nograles, K.E., Pierson, K.C., Mitsui, H., Pensabene, C.A., Kzhyshkowska, J., Krueger, J.G., Lowes, M.A., A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J. Invest. Dermatol. 130:10 (2010), 2412–2422.
23. [23] Sumida, H., Yanagida, K., Kita, Y., Abe, J., Matsushima, K., Nakamura, M., Ishii, S., Sato, S., Shimizu, T., Interplay between CXCR2 and BLT1 facilitates neutrophil infiltration and resultant keratinocyte activation in a murine model of imiquimod-induced psoriasis. J. Immunol. 192:9 (2014), 4361–4369.
24. [24] Tauber, M., Viguier, M., Alimova, E., Petit, A., Liote, F., Smahi, A., Bachelez, H., Partial clinical response to anakinra in severe palmoplantar pustular psoriasis. Br. J. Dermatol. 171:3 (2014), 646–649.
25. [25] Saunier, J., Debarbieux, S., Jullien, D., Garnier, L., Dalle, S., Thomas, L., Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra. Dermatology 230:2 (2015), 97–100.
26. [26] Witte, E., Kokolakis, G., Witte, K., Philipp, S., Doecke, W.D., Babel, N., Wittig, B.M., Warszawska, K., Kurek, A., Erdmann-Keding, M., Kunz, S., Asadullah, K., Kadin, M.E., Volk, H.D., Sterry, W., Wolk, K., Sabat, R., IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J. Invest. Dermatol. 134:11 (2014), 2757–2767.
27. [27] Hasegawa, E., Sonoda, K.H., Shichita, T., Morita, R., Sekiya, T., Kimura, A., Oshima, Y., Takeda, A., Yoshimura, T., Yoshida, S., Ishibashi, T., Yoshimura, A., IL-23-independent induction of IL-17 from gammadeltaT cells and innate lymphoid cells promotes experimental intraocular neovascularization. J. Immunol. 190:4 (2013), 1778–1787.
28. [28] Sabat, R., Ouyang, W., Wolk, K., Therapeutic opportunities of the IL-22-IL-22R1 system. Nat. Rev. Drug Discov. 13:1 (2014), 21–38.